ライフサイエンスコーパス: cancer-bearing

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 amplified breast cancer cell lines and other cancers bearing 11q13 amplification inhibited proliferat

2 Cancers bearing activated EGFR can be effectively target

3 tient (index patient) with metastatic breast cancer bearing an activating PIK3CA (phosphatidylinosito

4 s a role in the onset of muscle depletion in cancer-bearing animals and in glucocorticoid-induced atr

5 ic options for treating colorectal and other cancers bearing appropriate cation transporters.

6 ng improved therapies for patients with lung cancers bearing EGFR mutations.

7 therapy that involves administration to the cancer-bearing host of immune cells with direct anticanc

8 d-derived suppressor cells (MDSCs) expand in cancer-bearing hosts and contribute to tumor immune evas

9 The immunologic basis of NK-cell defects in cancer-bearing hosts has not been extensively studied.

10 lectively take up angiogenesis regulators in cancer-bearing hosts may have implications for the diagn

11 active T cells would inhibit tumor growth in cancer-bearing hosts.

12 le in the aberrant hematopoiesis observed in cancer-bearing hosts.

13 as led to encouraging therapeutic results in cancer-bearing hosts.

14 y between and within tumors as well as among cancer-bearing individuals, and all of these factors tog

15 treatment of the 30% of sporadic human lung cancers bearing LKB1 mutations.

16 targeting specifically VEGF-A, and in colon cancer-bearing mice (CT26) treated with drugs targeting

17 cells found in ascites of epithelial ovarian cancer-bearing mice at advanced stages of disease are im

18 ic angiogenesis induced by cav-1 in prostate cancer-bearing mice correlated with an increased frequen

19 d cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model.

20 n a two-phase solution system and in vivo in cancer-bearing mice indicates that the process of drug d

21 therapy regimen for the treatment of breast cancer-bearing mice prolonged the vaccine-induced progre

22 D11b(+)Gr-1(+) cells from ascites of ovarian cancer-bearing mice results in the significant regressio

23 imed CD4(+) T cells transferred into ovarian cancer-bearing mice secrete high levels of CCL5, which r

24 ografts and prolongs the survival of ovarian cancer-bearing mice.

25 uring the formation of metastatic lesions in cancer-bearing mice.

26 n as ferroptosis in starved cancer cells and cancer-bearing mice.

27 The study of both cancer-bearing mouse models in wild types and their corr

28 Unexpectedly, RER colon cancers bearing mutant p53 demonstrated the same stabili

29 heir utility to date is primarily limited to cancers bearing oncogenic kinase mutations.

30 of p53 is crucial for successful therapy of cancers bearing p53 mutations.

31 pecific pathways perturbed in the T cells of cancer-bearing patients will allow us to assess steps to

32 s with anti-tumour activity can be raised in cancer-bearing patients.

33 enotype and outcome among patients with lung cancer bearing similar mutations, suggesting that other

34 BET inhibitors in individuals with prostate cancer bearing SPOP mutations.

35 2-fold increase over normal expression among cancers bearing the corresponding chromosomal amplificat

36 Normal vascular endothelium in non-cancer-bearing tissue was consistently PSMA negative.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。